echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Inhibition of IL-12/IL-23 p40 subunits in skin and blood of patients with psoriasis by tofacitinib is dependent on studies of active interferon-gamma signaling in dendritic cells

    Inhibition of IL-12/IL-23 p40 subunits in skin and blood of patients with psoriasis by tofacitinib is dependent on studies of active interferon-gamma signaling in dendritic cells

    • Last Update: 2022-05-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Dendritic cells (DCs) are professional antigen-presenting cells that form the bridge between innate and acquired immunity


    Interleukin (IL)-12 and IL-23 are pro-inflammatory cytokines produced by dendritic cells (DCs) and have been implicated in the pathogenesis of psoriasis (Pso) and psoriatic arthritis (PsA)


    Taken together, our findings implicate a novel role for IFN-γ in the induction of tofacitinib inhibition of dendritic cell IL12B


    Source: Vincken NLA, Welsing PMJ, Silva-Cardoso SCSuppression of IL-12/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.